Solara Active

Which are the latest news on Solara Active?

Why is Solara Active Pharma Sciences Ltd falling/rising?

As of 05-Sep, Solara Active Pharma Sciences Ltd's stock price is rising to 640.00, reflecting a 1.58% increase due to positive financial performance and a trend reversal after previous declines. Despite a decline in investor participation, strong technical indicators and significant profit growth contribute to a favorable outlook for the stock.

As of 05-Sep, Solara Active Pharma Sciences Ltd's stock price is rising, currently at 640.00, reflecting a change of 9.95 (1.58%) upward. This increase can be attributed to several factors. Firstly, the stock has shown a positive performance today, outperforming its sector by 1.66%. Additionally, it has experienced a trend reversal, gaining after two consecutive days of decline, which may indicate renewed investor interest.<BR><BR>The stock reached an intraday high of Rs 651.2, marking a 3.36% increase, and is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a strong upward momentum. Furthermore, the company has reported significant growth in its financials, with a net profit increase of 69.9% and substantial growth in profit before tax and profit after tax compared to previous quarters. This positive financial performance, alongside a 25.26% growth in net sales over the last nine months, contributes to a favorable outlook for the stock.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 26.99% against the 5-day average. Despite this, the stock remains liquid enough for trading, indicating that there is still sufficient activity in the market. Overall, the combination of positive financial results, a trend reversal, and strong technical indicators are driving the stock's rise.

Who are in the management team of Solara Active?

The management team of Solara Active includes key members such as Jitesh Devendra and Poorvank Purohit as Managing Directors & CEOs, S Hariharan as Executive Director & CFO, and several independent and non-executive directors, including Aditya Puri as Chairman. This diverse team guides the strategic direction and management of the company.

The management team of Solara Active includes the following key members:<BR><BR>1. **Aditya Puri** - Chairman & Non-Executive Director<BR>2. **Nirmal P Bhogilal** - Independent Director<BR>3. **Vineeta Rai** - Independent Director<BR>4. **Rajagopalan Ramakrishnan** - Independent Non-Executive Director<BR>5. **Kausalya Santhanam** - Independent Director<BR>6. **Ankur Nand Thadani** - Non-Executive Director<BR>7. **Arun Kumar** - Non-Executive Director<BR>8. **S Hariharan** - Executive Director & CFO<BR>9. **Jitesh Devendra** - Managing Director & CEO<BR>10. **Poorvank Purohit** - Managing Director & CEO<BR>11. **Rajendra Kumar Srivastava** - Additional Director<BR>12. **Rajiv Vijay Naba** - Additional Director<BR><BR>This diverse team includes both executive and non-executive members, contributing to the strategic direction and management of the company.

What does Solara Active do?

Solara Active Pharma Sciences Ltd is a small-cap company specializing in the manufacturing and distribution of active pharmaceutical ingredients (APIs). As of June 2026, it reported net sales of 382 Cr and a net profit of 16 Cr, with a market cap of INR 2,966 Cr.

Overview:<BR>Solara Active Pharma Sciences Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing and distribution of active pharmaceutical ingredients (APIs).<BR><BR>History:<BR>The company was incorporated on February 23, 2017. The latest quarterly results reported net sales and profit for the period ending June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 382 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 16 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 2,966 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 710.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.51 <BR>Return on Equity: -0.12% <BR>Price to Book: 2.39 <BR><BR>Contact Details:<BR>Address: 201 Devavrata Sector 17 Vashi, Navi Mumbai Mumbai Maharashtra : 400703 <BR>Tel: 91-22-27892924 <BR>Email: investors@solara.co.in <BR>Website: http://www.solara.co.in

Who are the peers of the Solara Active?

Peers of Solara Active include Novartis India, Kwality Pharma, SMS Pharma, and others, with varying management and growth risks. Solara Active has a Below Average management risk and a 1-year return of 3.37%, significantly lower than Kwality Pharma's 231.75%.

Peers: The peers of Solara Active are Novartis India, Kwality Pharma, SMS Pharma, Advanced Enzyme, Ind-Swift Labs, Dishman Carbogen, Hikal, Fredun Pharma, and Panacea Biotec.<BR><BR>Quality Snapshot: Excellent management risk is observed at Novartis India and the rest have Average or Below Average management risk, with Average management risk found at Kwality Pharma, SMS Pharma, Advanced Enzyme, and Hikal, while Below Average management risk is noted for Solara Active, Ind-Swift Labs, Dishman Carbogen, Panacea Biotec. Growth ratings show Excellent growth at Fredun Pharma, while Good growth is seen at Novartis India, Average growth at Beta Drugs Ltd, and Below Average growth at Kwality Pharma, SMS Pharma, Advanced Enzyme, Ind-Swift Labs, Solara Active, Hikal, and Panacea Biotec. Capital Structure is Excellent at Novartis India, and Average at SMS Pharma, Ind-Swift Labs, and Hikal, while Below Average is noted for Solara Active, Dishman Carbogen, Fredun Pharma, and Panacea Biotec.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Kwality Pharma at 231.75%, while the lowest is Dishman Carbogen at -32.34%. Solara Active's own 1-year return is 3.37%, which is significantly lower than Kwality Pharma's but higher than Dishman Carbogen's. Additionally, Dishman Carbogen, Hikal, and Panacea Biotec have negative six-month returns.

How big is Solara Active?

As of 31st August, Solara Active Pharma Sciences Ltd has a market capitalization of 2,966.00 Cr and reported net sales of 1,431.43 Cr with a loss of 1.62 Cr over the latest four quarters.

As of 31st August, Solara Active Pharma Sciences Ltd has a market capitalization of 2,966.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Solara Active reported net sales of 1,431.43 Cr. However, the company experienced a loss of 1.62 Cr during the same period.<BR><BR>The latest reporting period for the balance sheet is March 2026, with shareholder's funds amounting to 1,252.88 Cr and total assets valued at 2,332.59 Cr.

Should I buy, sell or hold Solara Active Pharma Sciences Ltd?

Are Solara Active Pharma Sciences Ltd latest results good or bad?

Solara Active Pharma Sciences Ltd's latest Q1 FY27 results show a net profit of ₹16.31 crores, a 69.90% increase from the previous quarter, and a 19.57% year-on-year revenue growth, indicating a positive turnaround. However, concerns about long-term growth potential and high valuation persist, given past losses and stock underperformance.

Solara Active Pharma Sciences Ltd's latest results for Q1 FY27 show a mixed but generally positive performance. The company reported a net profit of ₹16.31 crores, which is a significant increase of 69.90% compared to the previous quarter. This marks a notable turnaround from the losses experienced in earlier quarters. Additionally, the revenue grew by 19.57% year-on-year, indicating strong underlying demand, although there was a slight sequential decline of 1.47% from the previous quarter.<BR><BR>Operating margins also improved, rising to 16.24%, up 135 basis points from the previous quarter, which reflects better cost management. However, despite these positive indicators, the company has faced challenges in the past, including a substantial loss of ₹566 crores in FY24, and its stock has underperformed compared to the broader Pharmaceuticals & Biotechnology sector.<BR><BR>While the quarterly results suggest a recovery and improved profitability, concerns remain about the company's long-term growth potential and capital efficiency. The elevated P/E ratio of 583 times compared to industry averages raises questions about valuation sustainability. Overall, the results can be seen as a step in the right direction, but the company still faces significant challenges that investors should consider.

When is the next results date for Solara Active Pharma Sciences Ltd?

The next results date for Solara Active Pharma Sciences Ltd is July 23, 2026.

The next results date for Solara Active Pharma Sciences Ltd is scheduled for July 23, 2026.

Is Solara Active technically bullish or bearish?

As of December 4, 2025, Solara Active's trend is neutral with mixed signals, showing a mildly bearish stance on weekly and monthly MACD and Bollinger Bands, while daily moving averages and On-Balance Volume suggest slight bullishness.

As of 4 December 2025, the technical trend for Solara Active has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across various indicators. The weekly MACD remains bearish, while the monthly MACD is mildly bearish. The RSI shows no signal on both weekly and monthly time frames. Bollinger Bands indicate a mildly bearish trend on both weekly and monthly charts. Daily moving averages are mildly bullish, providing some support. The KST is bearish weekly and mildly bearish monthly, while Dow Theory shows a mildly bearish weekly stance with no trend monthly. However, the On-Balance Volume (OBV) is bullish on both weekly and monthly time frames, suggesting some accumulation. Overall, the mixed indicators reflect a neutral stance with a slight inclination towards bullishness on the daily chart, but the prevailing sentiment remains cautious.

How has been the historical performance of Solara Active?

Solara Active's historical performance has shown significant fluctuations, with net sales declining from 1,616.88 Cr in Mar'21 to 1,283.76 Cr in Mar'25, but recent figures indicate a potential recovery in profitability and cash flow, with profit before tax and profit after tax turning positive in Mar'25 after previous losses. Total liabilities decreased, and cash flow from operating activities improved to 212.00 Cr in Mar'25.

Answer:<BR>The historical performance of Solara Active shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Solara Active's net sales have seen a decline from 1,616.88 Cr in Mar'21 to 1,283.76 Cr in Mar'25, with a notable drop from 1,443.81 Cr in Mar'23. The total operating income followed a similar trend, decreasing from 1,616.88 Cr in Mar'21 to 1,283.76 Cr in Mar'25. Operating profit (PBDIT) also experienced volatility, peaking at 414.64 Cr in Mar'21 before falling to 214.60 Cr in Mar'25, with a significant loss of -89.81 Cr in Mar'24. Profit before tax turned positive again in Mar'25 at 0.54 Cr after a series of losses, while profit after tax showed a recovery to 0.54 Cr from a substantial loss of -566.96 Cr in Mar'24. The company's total liabilities decreased from 2,820.72 Cr in Mar'23 to 2,231.84 Cr in Mar'25, indicating a reduction in debt levels. Cash flow from operating activities improved to 212.00 Cr in Mar'25 compared to 108.00 Cr in Mar'24, although the net cash outflow was -4.00 Cr in Mar'25. Overall, while Solara Active has faced challenges, recent figures suggest a potential recovery in profitability and cash flow.

Is Solara Active overvalued or undervalued?

As of November 7, 2025, Solara Active is considered overvalued due to its high PE ratio of 318.76, an EV to EBITDA of 38.62, and a PEG ratio of 3.13, all significantly higher than its peers, alongside a disappointing year-to-date return of -16.41%.

As of 7 November 2025, Solara Active's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently overvalued, primarily due to its exceptionally high PE ratio of 318.76, which is significantly higher than its peers. In comparison, Sun Pharma has a PE ratio of 35.17, while Cipla boasts a much lower PE of 22.33, highlighting the disparity in valuation.<BR><BR>Additionally, Solara's EV to EBITDA stands at 38.62, again placing it in a less favorable position compared to its peers like Dr. Reddy's Labs, which has an EV to EBITDA of 10.52. The PEG ratio of 3.13 further underscores the overvaluation, especially when compared to Cipla's PEG of 1.25. Recent stock performance has also been underwhelming, with a year-to-date return of -16.41% compared to a 6.50% gain in the Sensex, reinforcing the notion that Solara Active is currently overvalued in the market.

Who are the top shareholders of the Solara Active?

The top shareholders of Solara Active include Devicam Capital LLP with 15.53%, individual investors with 23.07%, and 55 foreign institutional investors holding 14.63%. Notably, Spiracca Ventures LLP holds 7.72%, and 34.64% of promoter holdings are pledged.

The top shareholders of Solara Active include a mix of institutional and individual investors. The largest promoter is Devicam Capital LLP, holding 15.53%. Additionally, there are significant holdings from individual investors, who collectively own 23.07%. The company also has 55 foreign institutional investors (FIIs) with a combined holding of 14.63%. Among public shareholders, Spiracca Ventures LLP stands out with a holding of 7.72%. It's worth noting that a portion of the promoter holdings, specifically 34.6353%, is pledged.

Has Solara Active declared dividend?

Yes, Solara Active Pharma Sciences Ltd has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of August 18, 2021. However, the dividend yield is 0%, and total returns over various periods have shown mixed performance, including significant losses in some cases.

Solara Active Pharma Sciences Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 18 Aug 21<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -39.77%, the dividend return was 0%, resulting in a total return of -39.77%.<BR><BR>For the 1-year period, the price return was 11.99%, the dividend return was 0%, leading to a total return of 11.99%.<BR><BR>Over the 2-year period, the price return was 39.98%, the dividend return was 0%, culminating in a total return of 39.98%.<BR><BR>In the 3-year period, the price return was 25.28%, the dividend return was 0%, which resulted in a total return of 25.28%.<BR><BR>During the 4-year period, the price return was -71.6%, the dividend return was 0.18%, resulting in a total return of -71.42%.<BR><BR>For the 5-year period, the price return was -11.39%, the dividend return was 1.45%, leading to a total return of -9.94%.<BR><BR>Overall, while Solara Active has declared a dividend, the dividend yield remains at 0%, indicating that recent performance has not significantly benefited shareholders in terms of returns. The total returns show a mixed performance over various periods, with some periods reflecting substantial losses.